Biology subjects

Debski-Antoniak, O.

Publications and source records attributed to Debski-Antoniak, O..

3 recordsLinked to original sources

bioRxiv2025

The gH/gL/gO Complex of Elephant Endotheliotropic Herpesvirus 1A Functions as a Receptor Binding Complex

Elephant endotheliotropic herpesvirus (EEHV) causes a fatal haemorrhagic disease in young elephants and represents a major threat to the survival of these endangered species. Despite its clinical importance, the mechanisms of EEHV entry and host cell recognition remain poorly understood. Here, we show that the EEHV1A homolog of the Betaherpesvirus glycoprotein O (gO) assembles with glycoproteins H and L (gH/gL) to form a heterotrimeric complex analogous to the human cytomegalovirus (HCMV) gH/gL/gO trimer. Using single-particle cryo-electron microscopy, we determined the structure of the EEHV1A gH/gL/gO complex at 3.2 [A] resolution, revealing a conserved overall architecture but distinct gO topology and disulfide arrangement. The EEHV1A trimer, but not gH/gL alone, bound primary elephant endothelial cells, monocytes, and lymphocytes, indicating that gH/gL/gO serves as the receptor-binding complex of EEHV1A. This binding was specifically blocked by sera from naturally infected elephants, confirming its antigenic relevance. Finally, negative-stain electron microscopy polyclonal epitope mapping of gH/gL/gO-Fab complexes identified a Fab population that bound gO near the apex of the gH/gL/gO trimer, suggesting that these antibodies may interfere with gH/gL/gO-receptor interactions. Together, these findings define the molecular architecture and receptor-binding properties of the EEHV1A gH/gL/gO complex and provide a structural framework for the development of vaccines and antibody-based interventions against EEHV-associated disease.

microbiology↗

bioRxiv2025

Adhirons are efficient tools to guide antiviral ligand discovery

Adhirons are small, antibody-like proteins expressed in bacteria that bind to biological targets with high affinity. Since their discovery, Adhirons have been isolated against over 350 targets, and they can be used for many research applications. However, their therapeutic application is at present in its early stages, hence the interest in developing novel small molecules to mimic their effect. We developed a pipeline for small molecule discovery where Adhirons act as starting templates in a ligand-based virtual screening workflow. For proof of concept, we used Adhirons against two viral systems: Crimean-Congo Haemorrhagic Fever Virus and Influenza A Virus. In both cases, a hit was identified from the mimics using biophysical and cell-based assays, highlighting how Adhirons, commercial libraries and structural approaches can be combined to accelerate small molecule inhibitor discovery of viruses.

cell biology↗

bioRxiv2023

Exploiting the Affimer platform against influenza A virus

Influenza A virus (IAV) is well known for its pandemic potential. While current surveillance and vaccination strategies are highly effective, therapeutic approaches are short-lived due to the high mutation rates of IAV. Currently, monoclonal antibodies (mAbs) have emerged as a promising approach to tackle future IAV pandemics. Additionally, several antibody-like alternatives exist that aim to improve upon mAbs. Affimers, one such alternative, benefit from a short development time, high expression levels in E. coli, and complete animal-free production. Here we exploited the Affimer platform to isolate and produce specific and potent inhibitors of IAV. Starting from a monomeric version of the IAV trimeric hemagglutinin (HA) fusion protein, we isolated 12 Affimers that inhibit IAV H3 subtype infection in vitro. Two of these Affimers were characterised in detail: they exhibited binding affinities to the target H3 HA protein in the nM range and bound specifically to the HA1 head domain. Cryo-EM employing a novel spray approach to prepare cryo-grids allowed us to image HA-Affimer complexes. Combined with functional assays, we determined that the mode of inhibition of these Affimers is based on blocking the interaction of HA to the host-cell receptor - sialic acid. Additionally, these Affimers inhibited IAV strains closely related to the one employed for Affimer isolation. Overall, these results support the use of Affimers as an alternative to existing targeted therapies for IAV and pave the way for their use as diagnostic reagents. ImportanceInfluenza A virus is one of the few viruses that can cause devastating pandemics. Due to the high mutation rates of this virus, annual vaccination is required and antivirals are short-lived. Monoclonal antibodies present a promising approach to tackle influenza virus infections, but are associated with some limitations. To improve on this strategy, we explored the Affimer platform, which are antibody-like, bacterially made proteins. By performing phage-display against a monomeric version of influenza virus fusion protein, an established viral target, we were able to isolate Affimers that inhibit influenza virus infection in vitro. We characterised the mechanism of inhibition of the Affimers by challenging with related influenza virus strains. We additionally characterised an HA-Affimer complex structure, using a novel approach to prepare samples for cryo-electron microscopy. Overall, these results show that Affimers are a promising tool against influenza virus infection.

microbiology↗